XML 44 R54.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended
Apr. 11, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Mar. 31, 2020
USD ($)
Jan. 31, 2020
USD ($)
Aug. 30, 2019
USD ($)
Oct. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2015
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2019
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                     $ 1,327,274 $ 2,829,905    
Grant funding liability         $ 13,091,424           13,091,424     $ 6,065,212
AstraZeneca                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Revenues                     72,000 2,700,000    
Collaborative Arrangement, Product | ApolloBio                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Territory expansion option period     3 years                      
Proceeds received in upfront payment                 $ 19,400,000          
Upfront payment received                 23,000,000   23,000,000   $ 23,000,000  
Advisory fees                 960,000          
Additional revenue to be achieved                     $ 20,000,000      
Royalty period                     10 years      
Period from effective date for termination                     1 year      
Number of days written notice before termination                     90 days      
Collaborative Arrangement, Product | AstraZeneca                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Upfront payment received   $ 27,500,000               $ 27,500,000        
Anticipated development and regulatory event based payment receivable milestones                     $ 125,000,000      
Anticipated commercial event based payment receivable milestones                     115,000,000      
Number of additional products to be developed | product       2                    
Deferred revenue         62,000           62,000      
Foreign Tax Authority | Collaborative Arrangement, Product | ApolloBio                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Foreign corporate income taxes reducing upfront payment                 2,200,000          
Foreign non-corporate income taxes reducing upfront payment                 $ 1,400,000          
Lassa Fever And MERS Vaccine | Collaborative Arrangement, Product | Coalition for Epidemic Preparedness Innovations                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received $ 56,000,000                          
Collaborative agreement, period to receive funding for research and development 5 years                          
Funding received for research and development                     987,000 1,700,000    
Grant funding liability         4,400,000           4,400,000      
SARS-CoV-2/COVID-19 Vaccine | Collaborative Arrangement, Product | Coalition for Epidemic Preparedness Innovations                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Collaborative agreement, funding to be received           $ 9,000,000                
Funding received for research and development                     2,400,000      
Grant funding liability         2,900,000           2,900,000      
DNA-Encoded Monoclonal Antibody Technology | Collaborative Arrangement, Product | Bill And Melinda Gates Foundation                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Funding received for research and development             $ 1,100,000 $ 2,200,000     134,000 $ 1,100,000    
Grant funding liability         892,000           892,000      
CELLECTRA 3PSP Proprietary Smart Device | Collaborative Arrangement, Product | Bill And Melinda Gates Foundation                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Funding received for research and development         5,000,000           64,000      
Grant funding liability         $ 4,900,000           $ 4,900,000